Investigational drugs for assisting psychotherapy for posttraumatic stress disorder (PTSD): emerging approaches and shifting paradigms in the era of psychedelic medicine.
No abstract is available for this record.
Bibliographic context
Topics and keywords
Citation graph
0 referenced DOIs found in stored source metadata. 0 indexed papers cite this DOI.
Related papers
Psilocybin reduces fear memory and restores neuroplasticity in the hippocampus and medial prefrontal cortex.Journal of Psychopharmacology · 2026-06-27Community engagement as a foundation for implementation research for group psilocybin assisted therapy in New MexicoFrontiers in Public Health · 2026-06-16EE127 A REVIEW OF HEALTH ECONOMIC ANALYSES OF PSILOCYBIN, MIDOMAFETAMINE(MDMA), AND KETAMINE-BASED TREATMENTS FOR MENTAL HEALTH CAREValue in Health · 2026-05-31Rapid-acting interventions in treatment-resistant depression - a comparative review of esketamine and psilocybinJournal of Pre-Clinical and Clinical Research · 2026-05-11MDMA and psilocybin therapy rules have been relaxed. Here’s what might happen nextUnknown journal · 2026-06-28Psilocybin-assisted therapy in treatment-resistant depression: rapid remission, uncertain durability, and the next phase of clinical evidenceAnnals of Medicine and Surgery · 2026-06-17Psilocybin and Mental Health Outcomes: Scoping Review with ☸SAIMSARASAIMSARA Journal · 2026-06-14Prenatal stress, excitatory-inhibitory imbalance, and ADHD risk: a hypothesis-driven perspective on psilocybin-induced neuroplasticityTranslational Psychiatry · 2026-06-04